Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	1,664	1,397	1,015	829.25	660.12	443.31
Revenue Growth	41.15%	37.55%	22.44%	25.62%	48.91%	65.66%
Gross Profit Gross Profit Growth	1,269	1,086	776.86	560.53	454.21	326.23
Operating Income Operating Income Growth	944.49	816.29	551.48	337.57	289.43	275.9
Net Income Net Income Growth	413.6	316.89	444.09	281.59	202.13	402.71
Earnings Per Share EPS Growth	3.38	2.56	3.43	2.10	1.44	2.74
EPS Growth	-22.53%	-25.36%	63.33%	45.83%	-47.45%	201.10%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Royalties Royalties Growth	1,042	867.84	570.99	447.87	360.48	203.9
Sales of Proprietary Products Sales of Proprietary Products Growth	209.12	194.61	166.62	130.83	72.85	23.26
Sales of Bulk rHuPH20 Sales of Bulk rHuPH20 Growth	215.84	133.02	86.33	115.44	82.08	80.96
Sales of Device Partnered Products Sales of Device Partnered Products Growth	51.99	48.81	50.54	54.58	36.1	-
Revenue Under Collaborative Agreements Revenue Under Collaborative Agreements Growth	144.41	152.33	140.84	80.53	108.61	135.19
Revenue (Total) Revenue (Total) Growth	1,664	1,397	1,015	829.25	660.12	443.31

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	231	142.82	596.07	336	362.79	740.92
Total Debt Total Debt Growth	2,179	2,177	1,506	1,531	1,541	879.49
Net Cash (Debt) Net Cash Growth	-1,948	-2,034	-909.72	-1,195	-1,178	-138.57
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-15.93	-16.42	-7.03	-8.91	-8.38	-0.94

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	818.6	651.56	479.06	388.57	240.11	299.44
Capital Expenditures CapEx Growth	-12.37	-6.97	-10.7	-15.29	-4.81	-1.46
Free Cash Flow Free Cash Flow Growth	806.22	644.59	468.37	373.28	235.3	297.98
Free Cash Flow Growth	49.11%	37.62%	25.47%	58.64%	-21.04%	462.76%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	76.27%	77.78%	76.51%	67.59%	68.81%	73.59%
Operating Margin	56.77%	58.45%	54.32%	40.71%	43.84%	62.24%
Pretax Margin	35.06%	33.43%	54.87%	42.01%	37.71%	56.06%
Profit Margin	24.86%	22.69%	43.74%	33.96%	30.62%	90.84%
FCF Margin	48.46%	46.15%	46.13%	45.01%	35.64%	67.22%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	38.13	24.98	13.70	17.34	38.06	14.05
Forward PE	13.03	8.85	10.38	9.77	21.92	17.89
P/FCF Ratio	18.15	12.28	12.99	13.08	32.70	18.99
PS Ratio	8.80	5.67	5.99	5.89	11.66	12.76

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Aug 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error